Neil Kumar - 24 Dec 2024 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: BBIO
Reported as of: 24 Dec 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Dec 2024, 19:05:38 UTC
Prior SEC filing: 12 Dec 2024
Next SEC filing: 30 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Brian C. Stephenson, Attorney-in-Fact

Key filing fact

Neil Kumar filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 27 Dec 2024.

Key facts

This page summarizes Neil Kumar's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 27 Dec 2024, 19:05.

Change

Previous filing in this sequence was filed on 12 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBIO transaction

Common Stock

Gift

Transaction value: $0
Shares: -4,685,725
Change %: -96%
Price: $0.000000
Shares after: 211,718
Date: 24 Dec 2024
Ownership: Direct

BBIO transaction

Common Stock

Gift

Transaction value: $0
Shares: +4,685,725
Change %: +463%
Price: $0.000000
Shares after: 5,698,447
Date: 24 Dec 2024
Ownership: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1

BBIO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 995,686
Date: 24 Dec 2024
Ownership: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.